NellOne Therapeutics, Inc. (NellOne), a virtually integrated biopharmaceutical company commercializing a proprietary recombinant protein for treating inflammatory respiratory diseases, is pleased to announce that Dana Angeles will serve as an intern over the summer of 2023.

NellOne Therapeutics, Inc. (NellOne), a virtually integrated biopharmaceutical company commercializing a proprietary recombinant protein for treating inflammatory respiratory diseases, is pleased to announce that Dana Angeles will serve as an intern over the summer of 2023.

NellOne Therapeutics, Inc. (NellOne), a virtually integrated biopharmaceutical company commercializing a proprietary recombinant protein for treating inflammatory respiratory diseases, is pleased to announce that Mark D. Wienhold has joined the team.

NellOne Therapeutics, Inc. (NellOne), a virtually integrated biopharmaceutical company commercializing a proprietary recombinant protein for treating inflammatory respiratory diseases, is pleased to announce that Wren S Adkisson, MSN, has joined its Scientific Advisory Board.

NellOne Therapeutics, Inc. (NellOne), would not be where it is today without our angel investors. Get to know these incredible individuals who support our mission to relieve suffering and restore lives by returning damaged soft and hard tissue to its pre-injury state.

NellOne Therapeutics Inc. (NellOne) Chief Science Officer, Dr. Cymbeline (Bem) Culiat, to receive the prestigious “Most Influential Filipina Woman in the World” award from the Foundation for Filipina Women’s Network.

Dr. Cymbeline Culiat recently shared with Friends of ORNL how NellOne is pursuing a fast-track path toward obtaining approval of a new drug for human clinical trials through the FDA’s Coronavirus Treatment Acceleration Program.

NellOne Therapeutics Inc. (NellOne) Chief Science Officer, Dr. Cymbeline (Bem) Culiat, to discuss regenerative medicine at virtual lecture for Friends of ORNL.

[Knoxville, TN] October 2021- Bill Malkes, Chief Executive Officer of NellOne Therapeutics, is the recipient of the 2021 Innov865 Impact Award. The Innov865 Impact Award, presented by Verizon, celebrates innovation and entrepreneurship in the community by recognizing...

WVLT's Anne Brock recently sat down with NellOne Co-Founder and Chief Science Officer, Dr. Cymbeline "Bem" Culiat, on her research into healing after COVID-19 and her recently launched book, Designed to Heal, co-authored with physician and theologian Jennie McLaurin....

[Knoxville, TN], August 9, 2021 – 490 BioTech and NellOne Therapeutics, Inc., two leaders in Tennessee’s thriving entrepreneurial community and members of its growing biotechnology cluster, announced today they are expanding their partnership to fight against acute...

Dr. Cymbeline T. (Bem) Culiat, Co-Founder and Chief Science Officer for NellOne Therapeutics, Inc. (NellOne), along with pediatrician, and public health expert, Dr. Jennie A. McLaurin, co-authored a groundbreaking book,